Skip to content

Can LUCIFINE Finerenone Tablets Treat Diabetic Kidney Disease?

LUCIFINE finerenone tablets

Nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) LUCIFINE Finerenone is a potential innovative drug that reduces the harmful effects of overactive mineralocorticoid receptors (MR).

Basic Information About Lucifine Finerenone Tablets


1.LUCIFINE (Finerenone) is a nonsteroidal MRA indicated for reducing the risk of chronic kidney disease (stages 3 and 4 with albuminuria) progression, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with type 2 diabetes (T2D)-related chronic kidney disease.

2.In February 2023, Bayer announced the European Commission’s approval to expand the indication of Finerenone tablets in the EU. The expanded indication covers the early stages of chronic kidney disease associated with type 2 diabetes.


10mg/tablet, 30 tablets/box.


Store between 20°C to 25°C (68°F to 77°F); short-term transportation is allowed at temperatures ranging from 15°C to 30°C (59°F to 86°F).


1.The recommended starting dose is 10 mg or 20 mg once daily based on estimated glomerular filtration rate (eGFR) and serum potassium threshold.

2.Increase the dosage to the target dose of 20 mg once daily after 4 weeks based on eGFR and serum potassium threshold.

3.The tablets can be taken with or without food.

Adverse Reactions:

Adverse reactions occurring in ≥1% of patients in the LUCIFINE (Finerenone) group (with a higher frequency than the placebo group) include hyperkalemia, hypotension, and hyponatremia.


Concurrent use with potent CYP3A4 inhibitors.

Patients with adrenal insufficiency.


Hyperkalemia: Increased risk in patients with decreased renal function and elevated baseline potassium levels. Monitor serum potassium levels and adjust the dose as needed.

Grapefruit or grapefruit juice: Avoid simultaneous use.

Moderate or weak CYP3A4 inhibitors: Monitor blood potassium during initiation or dose adjustment of Kerendia (Finerenone) or during concomitant use with moderate or weak CYP3A4 inhibitors and adjust the Kerendia dose accordingly.

Potent or moderate CYP3A4 inducers: Avoid simultaneous use.


Not recommended.

Safety and Efficacy:

The FIDELIO-DKD study was conducted in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), evaluating the efficacy and safety of finerenone compared to a placebo. Both groups of patients received standard care, including glycemic control and maximal tolerated doses of renin-angiotensin system (RAS) blockade therapy, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).

The results demonstrated that the study met its primary endpoint. When combined with standard care, finerenone significantly reduced the composite primary endpoint risk of CKD progression, kidney failure, and kidney death compared to the placebo. Specifically, over a median follow-up of 2.6 years, finerenone reduced the risk of the composite outcome—defined as the first occurrence of kidney function decline, estimated glomerular filtration rate (eGFR) persistently decreasing by ≥40% from baseline for at least 4 weeks, and kidney death—by 18% compared to the placebo (HR=0.82; 95% CI: 0.73-0.93; p=0.0014). The number needed to treat to prevent one primary composite endpoint event at 36 months was 29 (95% CI: 16-166).

LUCIFINE finerenone tablets
LUCIFINE finerenone tablets

Who Makes Lucifine Finerenone Tablets And Are They Safe?

LUCIFINE Finerenone Tablets are produced by the well-known Laotian generic pharmaceutical factory, LUCIUS Pharmaceutical Co., Ltd. LUCIUS Pharmaceutical Co., Ltd., established in 2014 in the pharmaceutical hub of Hyderabad, India, boasts significant reserves of pharmaceutical technology and skilled personnel, making it one of the world’s leading companies in the field of generic pharmaceutical capabilities.

LUCIUS Pharmaceutical (Laos) Co., Ltd. has officially established a 25,000-square-meter factory in Laos, equipped with comprehensive facilities including a high-end formulation international project integrated formulation workshop, office building, staff dormitory, and a swimming pool.

The company’s business involves generic pharmaceuticals, including anti-tumor drugs, cardiovascular medications, hematology drugs, diabetes medications, dermatological drugs, men’s health medications, anti-aging medications, and more, with a portfolio of over 200 generic drugs. Its primary markets include India, China, the Middle East, Southeast Asia, Eastern Europe, Africa, among other countries. The company operates multiple online sales enterprises and sales companies, holding significant positions in the pharmaceutical market, such as being the largest pharmaceutical retail representative for Indian generic drugs in China, the largest pharmaceutical wholesale representative for Bangladeshi generic drugs in China, the largest online retail representative for Indian generic drugs in China, the largest wholesale representative for Indian, Bangladeshi, and Turkish drugs in the Hong Kong region, and the largest pharmaceutical wholesale representative for Indian drugs in the Korean market. The company also has over 30 medical representatives in various provinces across China. With a manufacturing capacity exceeding one billion tablets per year, it has a professional research and development team specializing in the development of various complex chemical and biological formulations.

Can Lucifine Finerenone Tablets Treat Diabetic Kidney Disease?

On October 26, 2020, Bayer held a global media briefing during the American Society of Nephrology’s 2020 Kidney Week to present the results of the FIDELIO-DKD Phase III clinical study for the investigational drug Finerenone. This presentation focused on the significant risks associated with the co-occurrence of chronic kidney disease and type 2 diabetes, shedding light on the latest findings from the FIDELIO-DKD Phase III clinical trial.

Dr. Richard Nkulikiyinka, the Clinical Development Head for Cardiology and Nephrology at Bayer in Germany, introduced Finerenone as an investigational, novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA). Research has shown that it can prevent various damages caused by the excessive activation of the mineralocorticoid receptor. The overactivation of this receptor leads to inflammation and fibrosis, which are significant factors in the damage to the kidneys and cardiovascular system.

Finerenone was discovered after screening over a million compounds, and it differs from existing mineralocorticoid receptor antagonists in that it is fundamentally non-steroidal, often referred to as a non-steroidal mineralocorticoid receptor antagonist. Extensive animal studies have shown its effective anti-inflammatory and anti-fibrotic properties in both the kidneys and the heart. Moreover, Phase II clinical trial ARTS-DN demonstrated that it can improve a patient’s proteinuria without being influenced by blood pressure. Hence, when conducting the FIDELIO-DKD clinical study, it was assumed that the MR antagonistic action of this drug would slow the progression of kidney disease in chronic kidney disease and type 2 diabetes patients while reducing the incidence of cardiovascular disease and mortality.

Why Choose LUCIFINE Finerenone Tablets

It’s widely known that the treatment for type 2 diabetes, RYBELSUS® (semaglutide) tablets, comes with a high cost of up to $995 for 30 tablets. Similarly, the medication for treating diabetic kidney disease, Kerendia finerenone tablets, can be as expensive as $670 for 30 tablets. The exorbitant prices of these medications undoubtedly add to the challenges faced by patients in their daily lives.

Is there an equally effective but more affordable medication available? The answer is LUCIFINE finerenone tablets produced by Lucius Pharmaceuticals. LUCIFINE finerenone tablets are a diabetes kidney disease treatment that has received approval from the Laotian Ministry of Health and is manufactured in Lucius Pharmaceuticals’ GMP factory in Laos, as approved by the U.S. FDA.

LUCIFINE finerenone tablets are not only a legitimately authorized medication but also come at a very affordable price, being only one-third the cost of Kerendia finerenone tablets while delivering the same efficacy.

DKD Care Center serves as the authoritative global distributor for LUCIFINE finerenone tablets, and we possess the necessary authorization certificates from Lucius Pharmaceuticals. The introduction of this new medication comes with significant discounts. If you have been suffering from diabetic kidney disease for an extended period, please don’t hesitate to contact us promptly:

Phone: +852 6993858

Whatsapp: +856 9506 4225



Leave a Reply

Your email address will not be published. Required fields are marked *